Klaus Reither

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

Martin J. Boeree, Norbert Heinrich, Rob E. Aarnoutse et al. · The Lancet Infectious Diseases · 2016 · 379 citations · Full text

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt et al. · The Lancet · 2015 · 248 citations

Pulmonary Tuberculosis, Phase 2B, Tuberculosis Prevention +9

Preferential infection and depletion of <i>Mycobacterium tuberculosis</i> –specific CD4 T cells after HIV-1 infection

Christof Geldmacher, Njabulo Ngwenyama, Alexandra Schuetz et al. · The Journal of Experimental Medicine · 2010 · 233 citations · Full text

Rapid and Accurate Detection of Mycobacterium tuberculosis in Sputum Samples by Cepheid Xpert MTB/RIF Assay—A Clinical Validation Study

Andrea Rachow, Alimuddin Zumla, Norbert Heinrich et al. · PLoS ONE · 2011 · 161 citations · Full text

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

Conor Tweed, Rodney Dawson, Divan A. Burger et al. · The Lancet Respiratory Medicine · 2019 · 143 citations · Full text